425 related articles for article (PubMed ID: 29164670)
41. The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.
Rumi E; Trotti C; Vanni D; Casetti IC; Pietra D; Sant'Antonio E
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255170
[TBL] [Abstract][Full Text] [Related]
42. Genetic-pathologic characterization of myeloproliferative neoplasms.
Kim Y; Park J; Jo I; Lee GD; Kim J; Kwon A; Choi H; Jang W; Chae H; Han K; Eom KS; Cho BS; Lee SE; Yang J; Shin SH; Kim H; Ko YH; Park H; Jin JY; Lee S; Jekarl DW; Yahng SA; Kim M
Exp Mol Med; 2016 Jul; 48(7):e247. PubMed ID: 27444979
[TBL] [Abstract][Full Text] [Related]
43. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
[TBL] [Abstract][Full Text] [Related]
44. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
[No Abstract] [Full Text] [Related]
45. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
46. The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in
Pan Y; Wang X; Wen S; Liu X; Yang L; Luo J
Hematology; 2022 Dec; 27(1):902-908. PubMed ID: 36000955
[TBL] [Abstract][Full Text] [Related]
47. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
Guglielmelli P; Lasho TL; Rotunno G; Score J; Mannarelli C; Pancrazzi A; Biamonte F; Pardanani A; Zoi K; Reiter A; Duncombe A; Fanelli T; Pietra D; Rumi E; Finke C; Gangat N; Ketterling RP; Knudson RA; Hanson CA; Bosi A; Pereira A; Manfredini R; Cervantes F; Barosi G; Cazzola M; Cross NC; Vannucchi AM; Tefferi A
Leukemia; 2014 Sep; 28(9):1804-10. PubMed ID: 24549259
[TBL] [Abstract][Full Text] [Related]
48. Calreticulin mutations in Chinese with primary myelofibrosis.
Li B; Xu J; Wang J; Gale RP; Xu Z; Cui Y; Yang L; Xing R; Ai X; Qin T; Zhang Y; Zhang P; Xiao Z
Haematologica; 2014 Nov; 99(11):1697-700. PubMed ID: 24997152
[TBL] [Abstract][Full Text] [Related]
49. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
[TBL] [Abstract][Full Text] [Related]
50. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
51. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
52. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
Patel KP; Newberry KJ; Luthra R; Jabbour E; Pierce S; Cortes J; Singh R; Mehrotra M; Routbort MJ; Luthra M; Manshouri T; Santos FP; Kantarjian H; Verstovsek S
Blood; 2015 Aug; 126(6):790-7. PubMed ID: 26124496
[TBL] [Abstract][Full Text] [Related]
53. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
54. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
55. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
56. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
57. [New disease markers within the chronic myeloproliferative neoplasms].
Holmström MO; Ocias LF; Kallenbach K; Kjær L; Kristensen TK; Pallisgaard N; Petersen BL; Skov V; de Stricker K; Larsen TS; Hasselbalch HC
Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967091
[TBL] [Abstract][Full Text] [Related]
58. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
59. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM
Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853
[TBL] [Abstract][Full Text] [Related]
60. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]